Study_Mentioned
stringlengths 3
205
⌀ | Product_Mentioned
stringlengths 3
429
⌀ | Company_Mentioned
stringlengths 3
288
| Indication_Mentioned
stringlengths 2
111
| Non_Social
int64 1
1
| Tag
stringlengths 2
1.13k
⌀ | Adjusted_Date
stringlengths 11
16
| Conversation_Id
float64 422,000,000B
1,680,000,000B
| Clean_Tweet
stringlengths 1
298
⌀ | Profile_Bio
stringlengths 1
185
⌀ | Class
stringclasses 6
values | User_Type
stringclasses 17
values |
|---|---|---|---|---|---|---|---|---|---|---|---|
Not Tagged | Not Tagged | abbvie | lymphoma,myeloid | 1 | ['leukemia', 'cll', 'abbvie'] | 6/5/2022 10:09 | 1,530,000,000,000,000,000 | the correct answer is c) 20,000 25,000. around 21,160 new cases of chronic lymphocytic #leukemia (#cll) are estimated in the u.s. for this year. to learn more about cll, visit for valuable information and resources. #asco22 | Official Twitter Site for Pharmacyclics, an AbbVie Company.
Review our community guidelines here: https://t.co/yF1pVcUTKO | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | abbvie | Not Tagged | 1 | ['abbvie'] | 6/5/2022 14:52 | 1,530,000,000,000,000,000 | best #asco22 latte & art you're welcome... | Helping entrepreneurs & digital health companies improve the lives of more patients. Venture Partner @RefineryVC; CEO @PictureHealthAI; Tweets are my own | Individual | Advocacy / Charity |
LUMINOSITY | telisotuzumab | abbvie | Not Tagged | 1 | [] | 6/6/2022 13:54 | 1,530,000,000,000,000,000 | #asco22 key slide here for teliso-v. previously reported that squamous cohort met futility (rr 11.1%) and here, #egfr mt cohort also at futility. in egfr wt cohort, efficacy seen (cmet high, rr 52%). | Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him | Individual | HCP |
LUMINOSITY | telisotuzumab | abbvie | not tagged | 1 | ['telisotuzumab', 'abbvie'] | 6/7/2022 23:13 | 1,530,000,000,000,000,000 | 2022 updates:
at the ongoing #asco 2022 meeting, presented an interim analysis from the phase i & phase ii luminosity trial of #telisotuzumab vedotin (teliso-v). visit for more at: #asco #asco02022 #oncology #cancer | #DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry | Company / Organization | Consulting / Analytics |
not tagged | not tagged | abbvie | not tagged | 1 | ['thanks', 'abbvie'] | 6/7/2022 15:30 | 1,530,000,000,000,000,000 | as #asco22 comes to an end, we want to extend our thanks to all the #researchers and partners who have helped us along the way to share the latest data from our #bloodcancer portfolio & pipeline. | Official Twitter Site for Pharmacyclics, an AbbVie Company.
Review our community guidelines here: https://t.co/yF1pVcUTKO | Company / Organization | Pharma / Biotech |
a071102 | abt-888 | abbvie | other | 1 | ['2001'] | 6/7/2022 9:38 | 1,530,000,000,000,000,000 | her2 targeting 2001 versus 2022 #asco22 | Professor of Translational Oncology and Consultant Medical Oncologist | Individual | HCP |
not tagged | not tagged | abbvie | not tagged | 1 | ['inspire', 'abbvie'] | 6/7/2022 9:00 | 1,530,000,000,000,000,000 | as #asco22 comes to an end, our #oncology team is more inspired than ever to make a remarkable impact. interested in shaping the future of oncology with us? unleash your potential at abbvie. learn more at | AbbVie’s Twitter feed featuring news and updates from our U.S. business. Intended for U.S. residents only. Review our guidelines here: https://t.co/CMljIbzTPP | Company / Organization | Pharma / Biotech |
a071102 | abt-888 | abbvie | myeloid,other | 1 | ['leusm', '2001', '#mpn', 'mpnsm', 'cml'] | 6/7/2022 8:51 | 1,530,000,000,000,000,000 | #asco22 #mpnsm #leusm radich: cepheid development rapid pcr testing after anthrax attacks (2001) and then got into bcr-abl testing. now being employed as relatively cheap testing method to dx/monitor cml therapy around the world. | Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG) | Individual | HCP |
not tagged | not tagged | abbvie | not tagged | 1 | ['abbvie'] | 6/7/2022 7:58 | 1,530,000,000,000,000,000 | cvs is double dipping. i bet you are on a copay accumulator | Rheumatology, patient advocate, administrator. collaborator; opinions my own. #I??MyRheumatologist | Individual | Advocacy / Charity |
Not Tagged | elotuzumab | abbvie,bms | multiple myeloma | 1 | ['mmsm', 'elotuzumab'] | 6/6/2022 16:16 | 1,530,000,000,000,000,000 | congress #asco22 | samer ali srour presents a phase ii study of umbilical cord blood derived nk cells with elotuzumab, lenalidomide, and high-dose melphalan followed by asct in patients with high-risk #mm.
n=30. 2-year pfs and os rates were 83% and 97%.
#mmsm | The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma | Company / Organization | Healthcare |
Not Tagged | elotuzumab | abbvie,bms | multiple myeloma | 1 | ['mmsm', 'elotuzumab', '9091'] | 6/3/2022 9:59 | 1,530,000,000,000,000,000 | look forward to samer ali srour #asco22 presentation #multiplemyeloma #mmsm
nct01729091: phase 2: umbilical cord blood-derived nk cells, elotuzumab, len, melphalan f/b asct | Multiple Myeloma Education Platform for Myeloma Community | Company / Organization | Professional |
Not Tagged | elotuzumab | abbvie,bms | multiple myeloma | 1 | ['mmsm', 'elotuzumab'] | 6/6/2022 8:33 | 1,530,000,000,000,000,000 | #asco22 #mmsm srour: in vivo efficacy was wanting, hence exploration of adding elotuzumab in this ph2 study. | Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG) | Individual | HCP |
swog-1211 | elotuzumab | abbvie,bms | multiple myeloma | 1 | ['multiple myeloma', 'swog-1211', 'mmsm'] | 6/6/2022 10:30 | 1,530,000,000,000,000,000 | a great discussion was had with at #asco22 about swog-1211 for patients with newly diagnosed, high-risk multiple myeloma. #mmsm | | Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more. | Company / Organization | Publication / Journal |
Not Tagged | rovalpituzumab tesirine | abbvie,bms,amgen | Not Tagged | 1 | ['rova,(-approval)', '$amgn'] | 6/6/2022 14:14 | 1,530,000,000,000,000,000 | the spirit of rova-t... is there any reason to be optimistic about dll3? via from #asco22 $harp $amgn $allo | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
swog-1211 | elotuzumab,bortezomib | abbvie,bms,takeda | multiple myeloma | 1 | ['swog-1211', 'multiple myeloma', 'elotuzumab'] | 6/4/2022 10:26 | 1,530,000,000,000,000,000 | our is at #asco22 poster 477 sharing the results of a randomized phase ii trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple myeloma (swog-1211). if you can t swing by, dr. usmani shares insights below. | The official account of Memorial Sloan Kettering Cancer Center, the Sloan Kettering Institute, and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences | Company / Organization | Hospital / Clinic |
Not Tagged | Not Tagged | abbvie,daiichi sankyo | Not Tagged | 1 | ['abbvie', 'daiichisankyous'] | 6/3/2022 8:15 | 1,530,000,000,000,000,000 | we are grateful to our #asco22 sponsorship platinum donors: and ! your support of our mission to accelerate breakthroughs in #cancerresearch is critical to our success! | @ASCO's foundation funding research to conquer every cancer, for every patient, everywhere. | Company / Organization | Advocacy / Charity |
Not Tagged | Not Tagged | abbvie,daiichi sankyo | Not Tagged | 1 | ['daiichisankyous', 'daiichi', 'abbvie'] | 6/6/2022 8:00 | 1,530,000,000,000,000,000 | we are grateful to our #asco22 sponsorship platinum donors: and ! your support of our mission to accelerate breakthroughs in #cancerresearch is critical to our success! | @ASCO's foundation funding research to conquer every cancer, for every patient, everywhere. | Company / Organization | Advocacy / Charity |
Not Tagged | Not Tagged | abbvie,daiichi sankyo | Not Tagged | 1 | ['enhertu', '$dsnky', '$abbv'] | 6/5/2022 14:58 | 1,530,000,000,000,000,000 | $abbv $dsnky asco 2022 enhertu asks, how low can you go? | News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities | Individual | Finance / Investment |
Not Tagged | Not Tagged | abbvie,eli lilly,daiichi sankyo,astellas,gilead sciences | gi | 1 | [' vision', 'thank you', 'astellas', 'astellasus', 'abbvie', 'daiichisankyous', 'lillypad'] | 6/3/2022 11:15 | 1,530,000,000,000,000,000 | thank you, , , , , and , for supporting our mission as #asco22 track donors at the visionary level! we appreciate your generosity and vision! | @ASCO's foundation funding research to conquer every cancer, for every patient, everywhere. | Company / Organization | Advocacy / Charity |
Not Tagged | navitoclax | abbvie,evaluate pharma | Not Tagged | 1 | ['navitoclax', 'abbvie'] | 6/4/2022 19:27 | 1,530,000,000,000,000,000 | asco 2022 abbvie goes back to basics with navitoclax - evaluate pharma | Bill Bro: Kellogg Scholar, ASCO member, Paul Harris Fellow, @KidneyCancer Chair Emeritus & founder https://t.co/eNx9nq9BiC, CURING KIDNEY CANCER IN YOUR LIFETIME® | Individual | Healthcare |
epcore nhl-2 | epcoritamab | abbvie,genmab | lymphoma | 1 | ['lymsm', 'dlbcl', 'epcoritamab', 'lymphoma'] | 6/3/2022 16:24 | 1,530,000,000,000,000,000 | #hematology first-line treatment (tx) with subcutaneous (sc) #epcoritamab (epco) + r-chop in patients (pts) with high-risk diffuse large b-cell #lymphoma (#dlbcl): phase 1/2 data update #lymsm #asco22 | Lymphoma Unit @Hospital_FJD & @UICOquironsalud. Board member @sehh_es & @SIOGorg. Councilor @EHA_Hematology Executive Board. Chairman SWG “Aging and Hematology” | Individual | HCP |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['lymphoma', 'mantle,(-dismantle)', 'abbvie'] | 6/3/2022 7:26 | 1,530,000,000,000,000,000 | #asco22 j&j, abbvie detail a disease progression win for imbruvica in newly diagnosed mantle cell lymphoma. but does a lack of overall survival win matter? | Tweets from the Fierce Life Sciences editorial team | Company / Organization | Media / News |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['biotec', 'abbvie'] | 6/3/2022 12:05 | 1,530,000,000,000,000,000 | txbn news #asco22: imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival: johnson & johnson and abbvie popped the cork on some preliminary data showing imbruvica, ... #biotech #news | #LifeScience #news, #jobs and #events from the #Texas region, including #Dallas #Austin #Houston. Part of @BiotechNetworks, connecting #biotech since 2008. | Company / Organization | Media / News |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['biotec'] | 6/3/2022 12:28 | 1,530,000,000,000,000,000 | #asco22: imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #healthcare #biotech | Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines | Individual | Finance / Investment |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['party', 'abbvie'] | 6/3/2022 15:49 | 1,530,000,000,000,000,000 | j&j and abbvie popped the cork on some preliminary data at #asco22 showing imbruvica kept a rare and aggressive form of cancer at bay in combination with two other drugs for more than six years. but will overall survival data crash the party? | Biopharma reporter @endpts | Previously @LowellSun, @BostonGlobeMag, @DailyHampGaz, @telegramdotcom | @UMassAmherst grad | nicole@endpointsnews.com | Individual | Media / News |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['$jnj'] | 6/4/2022 11:45 | 1,530,000,000,000,000,000 | #asco22 and $jnj with #imbruvica no more lunar theme? | ASCO, ASH, EHA & ESMO Member - fr FT academic, traveller, foodie & now private practice! #girdad #boydad #hematology #oncology | Individual | HCP |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['import'] | 6/3/2022 5:00 | 1,530,000,000,000,000,000 | explore imbruvica find us at #asco22 booth #14099. click here for important safety information: and here for full prescribing information: | Please see full Prescribing Information here: https://t.co/zJOY8eGABA
Please see full Important Safety Information here: https://t.co/36tRNbbnkW
2/22 PRC-08915 | Company / Organization | Pharma / Biotech |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['import'] | 6/3/2022 5:00 | 1,530,000,000,000,000,000 | explore imbruvica find us at #asco22 booth #14099. click here for important safety information: and here for full prescribing information: | Please see full Prescribing Information here: https://t.co/zJOY8eGABA
Please see full Important Safety Information here: https://t.co/36tRNbbnkW
2/22 PRC-08915 | Company / Organization | Pharma / Biotech |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['import'] | 6/3/2022 5:00 | 1,530,000,000,000,000,000 | explore imbruvica find us at #asco22 booth #14099. click here for important safety information: and here for full prescribing information: | Please see full Prescribing Information here: https://t.co/zJOY8eGABA
Please see full Important Safety Information here: https://t.co/36tRNbbnkW
2/22 PRC-08915 | Company / Organization | Pharma / Biotech |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['import'] | 6/3/2022 5:00 | 1,530,000,000,000,000,000 | explore imbruvica find us at #asco22 booth #14099. click here for important safety information: and here for full prescribing information: | Please see full Prescribing Information here: https://t.co/zJOY8eGABA
Please see full Important Safety Information here: https://t.co/36tRNbbnkW
2/22 PRC-08915 | Company / Organization | Pharma / Biotech |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['import'] | 6/3/2022 5:00 | 1,530,000,000,000,000,000 | explore imbruvica find us at #asco22 booth #14099. click here for important safety information: and here for full prescribing information: | Please see full Prescribing Information here: https://t.co/zJOY8eGABA
Please see full Important Safety Information here: https://t.co/36tRNbbnkW
2/22 PRC-08915 | Company / Organization | Pharma / Biotech |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['import'] | 6/3/2022 5:00 | 1,530,000,000,000,000,000 | explore imbruvica find us at #asco22 booth #14099. click here for important safety information: and here for full prescribing information: | Please see full Prescribing Information here: https://t.co/zJOY8eGABA
Please see full Important Safety Information here: https://t.co/36tRNbbnkW
2/22 PRC-08915 | Company / Organization | Pharma / Biotech |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['lymphoma', '$abbv', 'abbvie', '$jnj'] | 6/3/2022 8:48 | 1,530,000,000,000,000,000 | $jnj $abbv asco: j&j, abbvie go back to imbruvica's roots in lymphoma. will lack of survival win matter? | News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities | Individual | Finance / Investment |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['lymphoma', 'abbvie'] | 6/3/2022 9:37 | 1,530,000,000,000,000,000 | asco: j&j, abbvie go back to imbruvica's roots in lymphoma. will lack of survival win matter? | The original site for employees in pharma, medical, and diagnostic sales and related industries. Join us and stay informed. | Company / Organization | Healthcare |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['lymphoma', 'abbvie'] | 6/3/2022 10:50 | 1,530,000,000,000,000,000 | asco: j&j, abbvie go back to imbruvica's roots in lymphoma. will lack of survival win matter? | Blogger | Individual | Finance / Investment |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['lymphoma', 'abbvie'] | 6/3/2022 10:50 | 1,530,000,000,000,000,000 | asco: j&j, abbvie go back to imbruvica's roots in lymphoma. will lack of survival win matter? | I am a digital marketer. | Individual | Blogger / Random / Other |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['lymphoma', 'abbvie'] | 6/3/2022 10:50 | 1,530,000,000,000,000,000 | asco: j&j, abbvie go back to imbruvica's roots in lymphoma. will lack of survival win matter? | Blogger and Writer | Individual | Finance / Investment |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['$abbv', '$jnj'] | 6/3/2022 13:42 | 1,530,000,000,000,000,000 | $jnj $abbv #asco22: imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival - | News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities | Individual | Finance / Investment |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['party', 'abbvie'] | 6/3/2022 15:00 | 1,530,000,000,000,000,000 | j&j and abbvie popped the cork on some preliminary data showing imbruvica kept a rare and aggressive form of cancer at bay in combination with two other drugs for more than six years. but will overall survival data crash the party? | The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs | Bot / Aggregator | Media / News |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['shine', 'mantle,(-dismantle)', 'jnjnews', 'biotec', 'abbvie'] | 6/3/2022 15:30 | 1,530,000,000,000,000,000 | imbruvica shines in first-line at as takes up mantle of elderly treatment #biotech #pharma #asco22 | Biopharma’s trusted news source. Lynn Yoffee, Jennifer Boggs, Anette Breindl, Michael Fitzhugh, Lee Landenberger, Randy Osborne, Mari Serebrov, Richard Staines | Company / Organization | Media / News |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['lymphoma', 'mantle,(-dismantle)', 'janssen', 'janssenglobal'] | 6/3/2022 21:00 | 1,530,000,000,000,000,000 | data presented at #asco22 put s #imbruvica out in front of other btk inhibitor for the first-line mantle cell lymphoma indication. | The leading voice for decision-makers throughout the global biopharma ecosystem.
Free weekly podcast "BioCentury This Week": https://t.co/6CfHh0mIT6 | Company / Organization | Consulting / Analytics |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | [] | 6/4/2022 6:57 | 1,530,000,000,000,000,000 | asco22: imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival #asco #btk #imbruvica #jamp #imbruvicas #asco22 | ? Follow @biztoc | Bot / Aggregator | Media / News |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | [] | 6/4/2022 10:21 | 1,530,000,000,000,000,000 | asco22: imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival | The Whole Business World on a Single Page.
By @thomas & Backed by @mcuban | Bot / Aggregator | Finance / Investment |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['abbvie', 'biotec'] | 6/4/2022 10:33 | 1,530,000,000,000,000,000 | abbvie and johnson & johnson want you to build a patient out of legos for the various indications imbruvica is approved to treat. nearly every biotech & pharma booth at #asco22 dedicates their booth to massive drug brand signs and very little about patients themselves. | covering the science, people, $ & biotechs behind new meds @Endpts | Tips? klahucik@endpointsnews.com | asking Q's, jogging 26.2 | ?? ?? ?? | he/him ?????? | Individual | Media / News |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['party', 'abbvie'] | 6/4/2022 11:00 | 1,530,000,000,000,000,000 | j&j and abbvie popped the cork on some preliminary data at #asco22 showing imbruvica kept a rare and aggressive form of cancer at bay in combination with two other drugs for more than six years. but will overall survival data crash the party? | The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs | Bot / Aggregator | Media / News |
Not Tagged | ibrutinib | abbvie,janssen | Not Tagged | 1 | ['ibru', 'abbvie'] | 6/4/2022 22:14 | 1,530,000,000,000,000,000 | having fun at #asco2022 #ibrutinib | Internal Medicine Resident Mount Auburn Hospital
Clinical Fellow Harvard Medical School
UNC Gillings & Imperial Medicine Alumna | Individual | HCP |
Not Tagged | Not Tagged | abbvie,janssen | lymphoma | 1 | ['lymphoma', 'mantle,(-dismantle)', '$jnj', '$abbv'] | 6/6/2022 7:30 | 1,530,000,000,000,000,000 | asco: johnson & johnson filed imbruvica for newly diagnosed mantle cell lymphoma with european authorities and is talking to the fda for a potential application! $jnj $abbv #pharma #oncology #asco | Investor Relations & PR firm working with growth #LifeSciences #Tech #Mining #Consumer companies to connect #WallStreet #Investors — No investment advice/DYODD | Company / Organization | Finance / Investment |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['lymphoma', 'abbvie'] | 6/6/2022 11:43 | 1,530,000,000,000,000,000 | asco: j&j, abbvie go back to imbruvica's roots in lymphoma. will lack of survival win matter? | An attorney representing patients who have suffered drug side effects or adverse drug reactions in drug injury lawsuits filed against pharmaceutical companies. | Individual | Advocacy / Charity |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['ibru', 'lymsm'] | 6/6/2022 13:30 | 1,530,000,000,000,000,000 | pod24 is adversely prognostic with induction, and early relapse adversely affects os. this has therapeutic implications, as evidenced by worse os when ibrutinib used in later relapse vs first relapse. #asco22 #lymsm | Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ?????? | Individual | HCP |
Not Tagged | ibrutinib | abbvie,janssen | lymphoma | 1 | ['ibru', 'lymsm'] | 6/6/2022 13:45 | 1,530,000,000,000,000,000 | with respect to the br+ibrutinib study presented at #asco22, there were more treatment-related deaths in the ibrutinib arm. #lymsm | Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ?????? | Individual | HCP |
swog-1211 | elotuzumab,bortezomib,lenalidomide | abbvie,merck,Takeda | multiple myeloma | 1 | ['swog-1211', 'elotuzumab'] | 6/4/2022 8:25 | 1,530,000,000,000,000,000 | #cedarssinaicancer at #asco22. dr. brian durie is co-author on the poster randomized phase ii trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high risk multiple #myeloma (swog-1211). | Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report. | Company / Organization | Hospital / Clinic |
transform-1,transform-2 | navitoclax,ruxolitinib | abbvie,novartis,incyte | Not Tagged | 1 | ['jakafi', 'rova', 'navitoclax', '$abbv'] | 6/4/2022 14:08 | 1,530,000,000,000,000,000 | note r/r navitoclax + jakafi data were published in jco last year. both settings now in ph3 (transform-1 & 2 trials). $abbv expects fda approval in 2023, per q4 deck #asco2022 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
Not Tagged | venetoclax | abbvie,roche | lymphoma | 1 | ['car-t', 'lymsm', 'venetoclax'] | 6/5/2022 17:28 | 1,530,000,000,000,000,000 | don't forget about car-t (although not enough f/u to see if responses are durable) and upcoming bites. remember: btki, venetoclax and immunotherapy don't work in fl! #lymsm #asco22 | Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ?????? | Individual | HCP |
Not Tagged | navitoclax,venetoclax | abbvie,roche,eli lilly,astrazeneca,zentalis pharma | Not Tagged | 1 | ['venclexta', 'navitoclax', '$lly', '$abbv', '$azn', '$zntl'] | 6/4/2022 17:25 | 1,530,000,000,000,000,000 | $abbv's navitoclax - the father of venclexta! - 23 years in the making. take on today's #asco22 data, plus some history $azn $zntl $lly | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
Not Tagged | ivosidenib,magrolimab,venetoclax,azacitidine | abbvie,roche,servier,gilead sciences | gi,myeloid | 1 | ['azacitidine,(-oral azaci),(-azacitidine oral)', 'ivosidenib', 'triplet', 'venetoclax', 'leukemia', 'leusm', 'aml,(-streamline),(-seamless),(-kamloops)', 'magrolimab'] | 6/4/2022 14:44 | 1,530,000,000,000,000,000 | addition of venetoclax +/- azacitidine to ivosidenib = responses in idh1 mutated aml promising activity of azacitidine + magrolimab with 50% mrd negativity looking forward for exciting triplets #asco22 #leukemia #leusm | Leukemia Fellow
MD Anderson Cancer Center, Houston | Individual | HCP |
Not Tagged | Not Tagged | abbvie,sanofi,xencor,genmab,janssen,roche | lymphoma | 1 | ['dlbcl', '$xncr', '$abbv', '$gmab', '$jnj', '$rhhby', '$regn'] | 6/3/2022 14:58 | 1,530,000,000,000,000,000 | the glofit dlbcl dataset $rhhby will soon take to the fda, via #asco22 $abbv $gmab $jnj $xncr $regn | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
Not Tagged | Not Tagged | abcellera | Not Tagged | 1 | ['$abcl'] | 6/5/2022 1:57 | 1,530,000,000,000,000,000 | #abcellera #asco22 will meet partners and discuss the latest research in #cancer care, #cd3 t cell panel #bispecific $abcl #biotech #aacr22 | disclaimer:
tweets are my own opinions and should not be seen as any investment advice and everything are associated with risks | Individual | Finance / Investment |
Not Tagged | Not Tagged | abion | other | 1 | ['breast', 'abion'] | 6/5/2022 11:03 | 1,530,000,000,000,000,000 | labn feed: agendia presents data from the flex real world evidence trial in seven posters at asco 2022, showcasing the power of its 30,000-patient breast cancer genome project: irvine, calif. & ... #losangeles #biotech | Los Angeles and Orange County #California #biotech news and events, for jobs follow @labnjobs #losangeles #orangecounty #lifescience | Bot / Aggregator | Media / News |
Not Tagged | adg-126 | adagene | Not Tagged | 1 | ['adagene'] | 6/3/2022 11:03 | 1,530,000,000,000,000,000 | #icymi: we published interim data for our masked, anti-ctla-4 program, adg126, at #asco. results from 16 patients in a monotherapy dose escalation show a compelling safety profile and antitumor activity. read the summary here: | Redefining the design and discovery of therapeutic antibodies #LifeIsMotion | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | adaptimmune | Not Tagged | 1 | ['thank you', 'adaptimmune'] | 6/5/2022 9:59 | 1,530,000,000,000,000,000 | today is #nationalcancersurvivorsday. we design and deliver new treatments options for people battling the disease. thank you to every patient who has taken or is taking part in our #clinicaltrials. #asco22 #immunotherapy | Adaptimmune is a multinational, clinical-stage #biotech company focused on developing novel immunotherapies that can potentially transform cancer treatment | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | adaptimmune | Not Tagged | 1 | ['$adap'] | 6/5/2022 13:15 | 1,530,000,000,000,000,000 | $adap #asco2022 link to the poster: | null | Bot / Aggregator | Blogger / Random / Other |
not tagged | afami-cel | adaptimmune | not tagged | 1 | ['afami-cel', 'adaptimmune'] | 6/6/2022 13:00 | 1,530,000,000,000,000,000 | update from adaptimmune on afami-cel, one step closer to bla for a tcr-t. median duration of response of 52 weeks #tcell #asco22 #tcr | VP, Discovery @ImmunoScape. Cell therapy. Immuno-Oncology. TCR T, CAR T. Opinions are my own. | Individual | Pharma / Biotech |
not tagged | not tagged | adaptimmune | not tagged | 1 | ['thank you', 'evolution', 'adaptimmune'] | 6/7/2022 10:46 | 1,530,000,000,000,000,000 | thank you #asco22! in this 5 minute interview ( gottlieb talks to about the evolution in #cancer care saying: the big story coming out of asco is the continued evolution in cell based therapy in cancer. #immunotherapy #oncology | Adaptimmune is a multinational, clinical-stage #biotech company focused on developing novel immunotherapies that can potentially transform cancer treatment | Company / Organization | Pharma / Biotech |
Not Tagged | afami-cel | adaptimmune | lymphoma,other | 1 | ['afami-cel', 'sarcoma', 'pivotal', 'adaptimmune'] | 6/3/2022 8:00 | 1,530,000,000,000,000,000 | today is the first day of #asco22 where we will present a poster showing longer pfs in a pooled analysis of patients with synovial sarcoma and mrcls treated with afami-cel in the pivotal spearhead-1 and phase 1 trials. #cancer #celltherapy #immunotherapy | Adaptimmune is a multinational, clinical-stage #biotech company focused on developing novel immunotherapies that can potentially transform cancer treatment | Company / Organization | Pharma / Biotech |
Not Tagged | Not Tagged | adaptive biotechnology | Not Tagged | 1 | [] | 6/3/2022 8:42 | 1,530,000,000,000,000,000 | $adpt news screener alert: the price is down after the recent publication posted about 17 hours ago . #stocksoftheday #stockalert #stocknews #cancer | Find the most important news and press releases about U.S. publicly-traded companies in real-time and stay ahead of the game! | Company / Organization | Finance / Investment |
Not Tagged | Not Tagged | adaptive biotechnology | Not Tagged | 1 | ['biotec'] | 6/3/2022 22:30 | 1,530,000,000,000,000,000 | adaptive #biotechnologies included in key abstracts at #asco 2022 supporting the role of the clonoseq #assay as a standard for mrd assessment technology [ ] #seattle-data from adaptive biotechnologies corporation (#nasdaq : | Journaliste Français indépendant installé en Suisse, Observateur spécialisé en analyse de reportages et de témoignages internationaux diffusé sur le web | Company / Organization | Blogger / Random / Other |
Not Tagged | Not Tagged | adaptive biotechnology | Not Tagged | 1 | ['biotec'] | 6/3/2022 8:40 | 1,530,000,000,000,000,000 | $adpt adaptive biotechnologies included in key abstracts at asco 2022 supporting the role of the clonoseq assay as a standard for mrd assessment technology | GetOnTrade is a news platform to help you stay up-to-date with the latest stock market news. We are not financial advisor(please do your own due diligence). | Bot / Aggregator | Finance / Investment |
Not Tagged | Not Tagged | adicet bio | lymphoma | 1 | ['lymphoma', 'adicet'] | 6/6/2022 6:03 | 1,530,000,000,000,000,000 | adicet $acet gamma-delta t cell therapy shows complete remissions in early study of lymphoma patients #asco22 | Reporter @statnews. I am the Night King of biotech. Data Are. Dog ??er. '21 Polk Award winner. Said one analyst: The likes of Adam Feuerstein attack viciously. | Individual | Media / News |
Not Tagged | adi-001 | adicet bio | other | 1 | [' adi-001', 'adi-001 ', '$acet'] | 6/6/2022 6:02 | 1,530,000,000,000,000,000 | $acet reports emerging data from adi-001 phase 1 trial at #asco22 adi-001 demonstrated 75% cr and orr rate across all dose levels with favorable safety and tolerability profile.
80% orr and cr rate at dose levels 2 and 3 combined. | Investor/trader focused primarily in the biopharma sector.
Tweets are not investment advice and are not recommendations of any kind. @BTGPremium | Individual | Finance / Investment |
not tagged | not tagged | adicet bio | not tagged | 1 | ['$acet'] | 6/6/2022 10:13 | 1,530,000,000,000,000,000 | if you were expecting something earth-shattering from $acet you'll be disappointed - durability remains unproven one way or the other. need more time & patients! my take on today's #asco22 update | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
not tagged | not tagged | adicet bio | not tagged | 1 | ['car-t', '$acet'] | 6/6/2022 8:17 | 1,470,000,000,000,000,000 | comparison - this is autologous anti-cd20 (not cd19) car-t - for $acet via discussant brian till #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
not tagged | not tagged | adicet bio | not tagged | 1 | ['car-t', 'adicet'] | 6/6/2022 10:55 | 1,530,000,000,000,000,000 | gene&cell therapy >> #asco22: early stock winner adicet reports crs for their off-the-shelf gamma delta car-t: adicet is getting center-ring attention today for its positive cut of the early data for their #lucidquest #genetherapy #celltherapy | Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines | Individual | Finance / Investment |
Not Tagged | adi-001 | adicet bio | lymphoma,other | 1 | ['lymphoma', ' adi-001', 'lymsm', 'adi-001 '] | 6/6/2022 15:22 | 1,530,000,000,000,000,000 | congress #asco22 | sattva swarup neelapu, md presents data from a phase i study of adi-001 in adult patients with r/r advanced b-cell #lymphoma. n=6
78% aes were of grade 1/2
orr=67%
cr=67% #lymsm #medicalcongress #cancerawareness | A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm | Company / Organization | Healthcare |
not tagged | not tagged | adicet bio | not tagged | 1 | ['$acet'] | 6/6/2022 6:00 | 1,470,000,000,000,000,000 | long-awaited #asco22 update from $acet: 2 more patients, 6/8 cr initially, but 1/5 cr at 6mth. nuance: 1 cr ongoing at >6mth
1 cr died of covid
1 cr relapsed 3 crs ongoing at <6mth
2 non responders | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
Not Tagged | adi-001 | adicet bio | other | 1 | ['cart,(-cartitude)', ' adi-001', 'adi-001 '] | 6/6/2022 6:03 | 1,530,000,000,000,000,000 | announces positive clinical data for adi-001 at #asco22. #celltherapy #cart #biotechnology | A clinical stage biotechnology company discovering and developing allogeneic gamma-delta T cell therapies for cancer. | Company / Organization | Pharma / Biotech |
Not Tagged | adi-001 | adicet bio | lymphoma,myeloid,other | 1 | ['7509', 'leukemia', ' adi-001', 'adi-001 ', 'lymphoma', 'cart,(-cartitude)', 'adicet'] | 6/3/2022 4:56 | 1,530,000,000,000,000,000 | #asco22 #immunotherapy future for #cd20 #bcell #leukemia #lymphoma expands with ph1 trial of adi-001 allogeneic gammadelta #tcell (abstract 7509). solves issues in making own #cart | Cancer specialist searching the world for better therapy | Individual | HCP |
Not Tagged | Not Tagged | adicet bio | lymphoma | 1 | ['lymphoma', 'adicet'] | 6/3/2022 22:17 | 1,530,000,000,000,000,000 | data hints at early promise for gamma delta cell therapy. #oncology #hematology #lymphoma #cancer #cancersucks | District Medical Group (DMG) is a nonprofit, independent medical group made up of more than 650 providers across all major medical and surgical specialties. | Company / Organization | Healthcare |
Not Tagged | adi-001 | adicet bio | other | 1 | ['cart,(-cartitude)', ' adi-001', 'adi-001 '] | 6/6/2022 6:09 | 1,530,000,000,000,000,000 | announces positive clinical data for adi-001 at #asco22. #celltherapy #cart #biotechnology | President and CEO of Adicet Bio. Excited to help deliver best in class gamma-delta T cell therapies for patients fighting cancer. | Individual | Pharma / Biotech |
not tagged | not tagged | adicet bio | not tagged | 1 | ['$acet'] | 6/6/2022 7:30 | 1,470,000,000,000,000,000 | $acet #asco22 presentation starts in 30 minutes. | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
GLEAN-1 | Fludarabine,Bendamustine | Adicet Bio | lymphoma | 1 | ['car-t', 'nhl', 'lymsm'] | 6/6/2022 8:05 | 1,530,000,000,000,000,000 | #asco22 #lymsm neelapu: glean-1 first in human study off the shelf allogeneic gamma delta car-t targeting cd20 for nhl. gdtcr is hla independent, lower risk of gvhd. enrolled pts with r/r high grade nhl w >2 prior regimens. n=8 evaluable so far | Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG) | Individual | HCP |
not tagged | not tagged | adicet bio | not tagged | 1 | ['$acet'] | 6/6/2022 8:12 | 1,470,000,000,000,000,000 | $acet conclusions & safety #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
not tagged | not tagged | adicet bio | not tagged | 1 | ['car-t', 'adicet'] | 6/6/2022 10:50 | 1,530,000,000,000,000,000 | #asco22: #adicet reports crs for their off-the-shelf #gammadelta #car-t #celltherapy #cancer | #BIOTECH Executive #GLOBALhealth advocate, #Startup enthusiast, #Cellandgene #Oncology #Genomics #healthTECH #MedTECH, columnist & speaker. Opinions MY own ! | Individual | Research / Science |
not tagged | not tagged | adicet bio | not tagged | 1 | ['$acet'] | 6/6/2022 6:01 | 1,530,000,000,000,000,000 | $acet keen to stress that the non-covid relapse was treated with local rt and remains cancer-free at >6mth. that's still a relapse, though. let the debate begin! #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
Not Tagged | adi-001 | adicet bio | other | 1 | [' adi-001', 'adi-001 ', '$acet'] | 6/6/2022 6:25 | 1,530,000,000,000,000,000 | $acet outlines data from adi-001 study at asco meeting | notrel?ad is an Ai-based web service that helps users automating public web content monitoring for investing and trading purposes. Not advice. Twitter delayed. | Bot / Aggregator | Finance / Investment |
Not Tagged | adi-001 | adicet bio | other | 1 | [' adi-001', 'adi-001 ', '$acet'] | 6/6/2022 8:14 | 1,470,000,000,000,000,000 | note: higher adi-001 dose level 4 has been added $acet #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
not tagged | not tagged | adicet bio | not tagged | 1 | ['$acet'] | 6/6/2022 8:26 | 1,470,000,000,000,000,000 | brian till mentioned the hla issue, but didn't really address relapses as a future focus $acet #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
not tagged | not tagged | adicet bio | not tagged | 1 | ['$acet'] | 6/6/2022 10:49 | 1,470,000,000,000,000,000 | here's the $acet discussant slide i was looking for re host-versus-graft #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
not tagged | not tagged | adicet bio | not tagged | 1 | ['car-t', '$acet', 'adicet'] | 6/6/2022 12:50 | 1,530,000,000,000,000,000 | $acet asco: adicet s gamma delta car-t therapy readout paves way for pioneering phase 2 trial | News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities | Individual | Finance / Investment |
Not Tagged | Not Tagged | adicet bio | lymphoma | 1 | ['lymphoma', '$acet', 'adicet'] | 6/6/2022 13:27 | 1,530,000,000,000,000,000 | adicet's gamma-delta cell therapy shows 75% cr rate in lymphoma trial $acet #asco22 | The latest global #pharma news, insights, analysis, and views providing you with an information edge. FirstWord Pharma. Where people who know first, go first. | Company / Organization | Media / News |
not tagged | not tagged | adicet bio | not tagged | 1 | ['$acet'] | 6/6/2022 14:49 | 1,530,000,000,000,000,000 | benda not mentioned here $acet #asco22 | Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today. | Individual | Finance / Investment |
Not Tagged | Not Tagged | adicet bio | lymphoma | 1 | ['lymphoma', '$acet', 'adicet'] | 6/6/2022 15:06 | 1,530,000,000,000,000,000 | adicet's gamma-delta cell therapy shows 75% cr rate in lymphoma trial $acet #asco22 | #IME #CME #healthcare #innovation #DotConnector https://t.co/Ag09XUbNP3 | Individual | Blogger / Random / Other |
not tagged | not tagged | adicet bio | not tagged | 1 | ['adicet'] | 6/6/2022 16:00 | 1,530,000,000,000,000,000 | adicet is getting center-ring attention today for its positive cut of the early data for their off-the-shelf gamma delta t cell player. | The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs | Bot / Aggregator | Media / News |
not tagged | not tagged | adicet bio | Not Tagged | 1 | ['car-t', 'cart,(-cartitude)'] | 6/6/2022 18:00 | 1,530,000,000,000,000,000 | asco: adicet s gamma delta car-t therapy readout paves way for pioneering phase 2 trial - more like this | #asco22 #cartcell #celltherapy #clinicaldata #biotech #genetherapy #biotechnology | Business intelligence for biotechs. We help #biotech innovators, investors, and business partners connect. | Company / Organization | Finance / Investment |
Not Tagged | adi-001 | adicet bio | other | 1 | [' adi-001', 'adi-001 ', 'adicet'] | 6/6/2022 19:49 | 1,530,000,000,000,000,000 | how 's adi-001 is stacking up v. other cd20-targeting new modality therapies at #asco22 via 's | Executive Editor, @BioCentury. Jersey boy happily ensconced in Cali. Dad. Failed poet. Devoted Iggles fan. Cats. @Princeton, @SAISHopkins alum. Opinions? Mine. | Individual | Publication / Journal |
Not Tagged | adi-001 | adicet bio | other | 1 | [' adi-001', 'adi-001 ', 'adicet'] | 6/6/2022 20:00 | 1,530,000,000,000,000,000 | how 's adi-001 is stacking up against other cd20-targeting new modality therapies at #asco22 | The leading voice for decision-makers throughout the global biopharma ecosystem.
Free weekly podcast "BioCentury This Week": https://t.co/6CfHh0mIT6 | Company / Organization | Consulting / Analytics |
Not Tagged | adi-001 | adicet bio | other | 1 | ['cart,(-cartitude)', ' adi-001', 'adi-001 ', 'adicet', 'adicetbio'] | 6/7/2022 17:06 | 1,530,000,000,000,000,000 | that s a wrap for #asco22!! it was wonderful to see top experts discussing adi-001 gamma-delta #cart cell data + all of the new advancements reviewed this week. here s to great scientific progress on behalf of patients. | A clinical stage biotechnology company discovering and developing allogeneic gamma-delta T cell therapies for cancer. | Company / Organization | Pharma / Biotech |
Not Tagged | adi-001 | adicet bio | other | 1 | ['adi001 ', 'adicet', '$acet', 'adicetbio'] | 6/7/2022 2:10 | 1,530,000,000,000,000,000 | #adicetbio reports emerging data from #adi001 phase 1 trial at the #asco22 $acet | Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders. | Company / Organization | Healthcare |
not tagged | not tagged | adicet bio,curis,immutep,janssen,legend biotech | not tagged | 1 | ['$immp', '$jnj', 'immutep', '$acet', 'legn', 'curis', '$cris', 'adicet'] | 6/6/2022 15:24 | 1,530,000,000,000,000,000 | $legn $jnj $acet $cris $immp legend/j&j, adicet, curis and immutep announce wins at asco | biospace #jobs | News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities | Individual | Finance / Investment |
not tagged | not tagged | adicet bio,roche,abbvie,janssen,gilead sciences | not tagged | 1 | ['$jnj', '$abbv', '$acet', 'gilead', '$gild', '$rhhby'] | 6/6/2022 11:15 | 1,530,000,000,000,000,000 | asco 2022: gilead s tough weekend, bispecific progress and gamma delta cell therapy by $gild $rhhby $jnj $abbv $acet | We provide in-depth insight into the most significant news and trends shaping biotech and pharma. Sign up here: https://t.co/F2W5HeStyV | Company / Organization | Media / News |
not tagged | adxs-503,pembrolizumab | advaxis,merck | thoracic | 1 | ['sclc', 'lcsm,(-blcsm)', 'adxs-503', 'lung', 'nsclc', 'award', 'pembro'] | 6/6/2022 9:07 | 1,530,000,000,000,000,000 | dr. aaron lisberg, recipient of 2019 cda award from lungevity, presents a poster about using adxs-503 immunotherapy to overcome resistance to pembro #asco22 #lcsm #nsclc | LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer. | Company / Organization | Advocacy / Charity |